Stroke: The anticoagulant effect of the dabiga group is reversed before the venous thrombolysis of the tenapu enzyme.

!---- dabiga is an effective and commonly used prescription drug to prevent atrial fibrillation thrombosisunlike vitamin K antagonists, it does not require anticoagulant monitoring and is effective quicklyIdaluzumab, a monoclonal antibody with a high affinity against the Dabiga group, has been shown to quickly and permanently reverse the anticoagulant effect of the Dabiga groupAlthough unreversed anticoagulants are a contraindication of lysobolic, limited literature suggests that it is safe to use idaluzumab before intravenous lypresse injections in acute ischemic stroke patientsthypenzyme is a genetically modified form of atepase with higher fibrin specificity and a longer half-life, and can be administered in a single pushcompared to the standard dose of atepasy, intravenous tinepase (0.25-0.40 mg/kg) increases the early reflux rate in patients with intracranial large vascular aplexys, which is safe for stroke patientsthypenzyme is most likely to be at least as bad as atatipase, although confirmation trials continueThere were only one single case of using thin-pupyrinasventhroem after reversing the anticoagulant effect of the dabbiga groupJames Behari, from New Zealand, and others reported on Stroke in May 2020 13 cases of ischemic stroke in the Dabiga group, who were given the treatment of the tenauzumab after idaruzumabthe study included 13 patients given to the denipine venous thrombolytic treatment after the anticoagulant effect of the continuous Idaluzumab anti-reversal dabiga group, from two centres in New Zealand and Australiaof these 13 patients, 9 were unmales, with an average age of 79 years, with an average NIHSS score of 6all 13 patients, atrial fibrillation was the cause of the use of dabbigalonger coagulation time (thrombin clotting time, TCT) in all patients (average not 80s)7 cases were large vascular aples and intravascular therapy was performed, of which 2 (29%) were refluxed early after the use of tinepenzyme, so intravascular thrombosis was not performedthe conversion of brain hemorrhage and symptomatic haemorrhage to 0 cases8 cases (62%) of patients achieved a good functional prognosis (mRS 0-2)two deaths from large-scale infarction the authors concluded that our experience suggests that for selected acute ischemic stroke patients, the anticoagulant effect of giving tinipase before using idaluzumab to reverse the dabiga group may be safe further research is needed to accurately estimate its effect and clinical lyse risk .